Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













Topiroxostat






●العربية
 ●فارسی
 ●日本語
 ●Tiếng Việt
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

Topiroxostat
Clinical data
Trade namesTopiloric, Uriadec
ATC code
  • None
Legal status
Legal status
  • Approved in Japan
Identifiers

  • 4-[5-(4-Pyridinyl)-1H-1,2,4-triazol-3-yl]-2-pyridinecarbonitrile

CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H8N6
Molar mass248.249 g·mol−1
3D model (JSmol)

  • C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N

  • InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)

  • Key:UBVZQGOVTLIHLH-UHFFFAOYSA-N

Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia.[1] It was approved for use in Japan in June 2013.[1]

Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.[2]

References[edit]

  1. ^ a b "New Drugs FY2013" (PDF). Pharmaceuticals and Medical Devices Agency, Japan. Archived from the original (PDF) on 2014-02-22. {{cite journal}}: Cite journal requires |journal= (help)
  • ^ Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. (December 2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. 18 (6): 876–84. doi:10.1007/s10157-014-0935-8. PMC 4271138. PMID 24448692.
    • Stub icon

    This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Topiroxostat&oldid=1125522824"
    Categories: 
    ●Drugs not assigned an ATC code
     ●Xanthine oxidase inhibitors
     ●Triazoles
     ●Pyridines
     ●Nitriles
     ●Musculoskeletal system drug stubs
     Hidden categories: 
    ●CS1 errors: missing periodical
     ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Articles containing unverified chemical infoboxes
     ●All stub articles
      


    ●This page was last edited on 4 December 2022, at 12:35 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki